Keyphrases
Acinetobacter Baumannii (A. baumannii)
25%
Aminoglycosides
25%
Antimicrobial
25%
Antimicrobial Resistance
50%
Astana
25%
Bacterial Isolates
25%
Bacterial Resistance
100%
Carbapenems
25%
Cefepime
50%
Ceftriaxone
25%
Country Report
100%
Developing Countries
100%
Enterococcus Faecalis
25%
Gram-negative Bacteria
25%
Gram-positive Bacteria
25%
High Resistance
25%
Hospital-acquired Infection
100%
Infection Control Program
25%
Intensive Care Unit
100%
Kazakhstan
100%
Oncology
25%
Pseudomonas Aeruginosa (P. aeruginosa)
25%
Rational Use
25%
Resistance Rate
25%
Retrospective Analysis
25%
Surveillance System
25%
Tertiary Hospital
100%
Transplantation
25%
Medicine and Dentistry
Acinetobacter Baumannii
25%
Aminoglycoside
25%
Antibiotic Resistance
100%
Antiinfective Agent
25%
Carbapenem Derivative
25%
Cefotaxime
25%
Ceftriaxone
25%
Cefuroxime
25%
Enterococcus faecalis
25%
Gram-Negative Bacteria
25%
Gram-Positive Bacteria
25%
Hospital Infection
100%
Infection Control
25%
Intensive Care Unit
100%
Oncology
25%
Pseudomonas aeruginosa
25%
Surveillance System
25%
Nursing and Health Professions
Aminoglycoside
25%
Antiinfective Agent
25%
Antimicrobial Resistance
50%
Carbapenem Derivative
25%
Cefotaxime
25%
Ceftriaxone
25%
Cefuroxime
25%
Hospital Infection
100%
Infection Control
25%
Intensive Care Unit
100%
Tertiary Care Center
100%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
25%
Aminoglycoside
25%
Antiinfective Agent
25%
Antimicrobial Resistance
50%
Carbapenem Derivative
25%
Cefotaxime
25%
Ceftriaxone
25%
Cefuroxime
25%
Enterococcus faecalis
25%
Gram Negative Bacterium
25%
Gram Positive Bacterium
25%
Hospital Infection
100%
Infection
25%
Pseudomonas aeruginosa
25%
Biochemistry, Genetics and Molecular Biology
Acinetobacter Baumannii
33%
Aminoglycoside
33%
Antibiotic Resistance
100%
Cefotaxime
33%
Ceftriaxone
33%
Enterococcus faecalis
33%
Gram Negative Bacterium
33%
Gram Positive Bacterium
33%
Pseudomonas aeruginosa
33%